Herzuma, which is a HER2/neu receptor antagonist biosimilar to Herceptin, has been approved to treat HER2-overexpressing breast cancer for certain indications. Celltrion CEO Woosung Kee said: “Biosimilars are
The post Teva, Celltrion get FDA nod for Roche’s breast cancer drug biosimilar appeared first on Pharmaceutical Business review.
Original Article: Teva, Celltrion get FDA nod for Roche’s breast cancer drug biosimilar